Yixintang Pharmaceutical Group Co., Ltd.
Symbol: 002727.SZ
SHZ
18.75
CNYMarket price today
23.9311
P/E Ratio
0.6980
PEG Ratio
11.17B
MRK Cap
- 0.02%
DIV Yield
Yixintang Pharmaceutical Group Co., Ltd. (002727-SZ) Financial Statements
Balance Sheet
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 3895.3 | 3520 | 2532.4 | |||||||||||||||
balance-sheet.row.short-term-investments | 0 | 219.7 | 8.4 | 297.3 | |||||||||||||||
balance-sheet.row.net-receivables | 0 | 1991.7 | 2411 | 1777.5 | |||||||||||||||
balance-sheet.row.inventory | 0 | 3852.6 | 3387.4 | 3317 | |||||||||||||||
balance-sheet.row.other-current-assets | 0 | 153.3 | 139.2 | 65.5 | |||||||||||||||
balance-sheet.row.total-current-assets | 0 | 9892.9 | 9457.6 | 7692.4 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 3995.6 | 3993.5 | 4080 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 1649.6 | 1397.2 | 1380 | |||||||||||||||
balance-sheet.row.intangible-assets | 0 | 184.1 | 165.7 | 122.9 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 1833.7 | 1562.9 | 1502.8 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | 165.3 | 131.4 | -190.1 | |||||||||||||||
balance-sheet.row.tax-assets | 0 | 88.9 | 94.1 | 58.5 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 670.8 | 939.5 | 1193.8 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 6754.5 | 6721.5 | 6645 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 0 | 16647.4 | 16179.1 | 14337.3 | |||||||||||||||
balance-sheet.row.account-payables | 0 | 2560.2 | 4328.8 | 3805.9 | |||||||||||||||
balance-sheet.row.short-term-debt | 0 | 3333.9 | 1335.5 | 1143.9 | |||||||||||||||
balance-sheet.row.tax-payables | 0 | 81.4 | 250.4 | 164.1 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 1552.2 | 1758.5 | 1764.1 | |||||||||||||||
Deferred Revenue Non Current | 0 | 1.2 | 12.2 | 13.3 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 0 | 1191.9 | 1055.8 | 12.7 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 1557.3 | 1774.7 | 1781 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 1552.2 | 1756.7 | 1729 | |||||||||||||||
balance-sheet.row.total-liab | 0 | 8757.1 | 8651.5 | 7664.8 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0 | 596 | 596 | 596.2 | |||||||||||||||
balance-sheet.row.retained-earnings | 0 | 4646.4 | 4335.4 | 3504.2 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 377.8 | 424.9 | 405.6 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 2125.8 | 2069.8 | 2071.7 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 7746 | 7426.1 | 6577.7 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 16647.4 | 16179.1 | 14337.3 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 131 | 101.4 | 94.8 | |||||||||||||||
balance-sheet.row.total-equity | 0 | 7877 | 7527.6 | 6672.5 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||
Total Investments | 0 | 385 | 139.8 | 107.2 | |||||||||||||||
balance-sheet.row.total-debt | 0 | 4886.1 | 3094 | 2908 | |||||||||||||||
balance-sheet.row.net-debt | 0 | 1210.5 | -417.6 | 672.9 |
Cash Flow Statement
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 549.4 | 1013 | 917.2 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 1000.6 | 1087.8 | |||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -35.1 | -27.3 | |||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 14.2 | 40.4 | |||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 0 | -9.7 | -603.9 | |||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | -765.8 | -739.7 | |||||||||||||||
cash-flows.row.inventory | 0 | 0 | -234.9 | -1236.8 | |||||||||||||||
cash-flows.row.account-payables | 0 | 0 | 1026.1 | 1399.9 | |||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | -35.1 | -27.3 | |||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -549.4 | 514.1 | 377.5 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -349 | -391.6 | |||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | -4.7 | -65.1 | |||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -980.5 | -1976.5 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 1207.2 | 2901.8 | |||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | -94.7 | -336.9 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | -221.7 | 131.7 | |||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -207.9 | -137.1 | |||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 2 | 0.1 | |||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -2 | -0.1 | |||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | -191.6 | -180.9 | |||||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | -678.6 | -986.8 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | -1078.2 | -1304.8 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0.3 | -0.1 | |||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 0 | 1197.5 | 618.5 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 2859.5 | 2859.5 | 1661.9 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 2859.5 | 1661.9 | 1043.5 | |||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 0 | 2497.1 | 1791.7 | |||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -349 | -391.6 | |||||||||||||||
cash-flows.row.free-cash-flow | 0 | 0 | 2148.1 | 1400 |
Income Statement Row
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 17301.4 | 17431.6 | 14587.4 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 11750.3 | 11322.3 | 9196.5 | |||||||||||||||
income-statement-row.row.gross-profit | 0 | 5551 | 6109.3 | 5390.9 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0 | -106.6 | 349.1 | 320.6 | |||||||||||||||
income-statement-row.row.operating-expenses | 0 | 4717.5 | 4496.8 | 4091.3 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 16467.8 | 15819.1 | 13287.8 | |||||||||||||||
income-statement-row.row.interest-income | 0 | -77.6 | 53.4 | 39.2 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 135.3 | 147.1 | 136.2 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -123.6 | -426.9 | 28.6 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -106.6 | 349.1 | 320.6 | |||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -123.6 | -426.9 | 28.6 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 135.3 | 147.1 | 136.2 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 1332.4 | 1000.6 | 1397.7 | |||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 0 | 833.5 | 1661.9 | 1067.9 | |||||||||||||||
income-statement-row.row.income-before-tax | 0 | 709.9 | 1235 | 1096.5 | |||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 142.2 | 222 | 179.3 | |||||||||||||||
income-statement-row.row.net-income | 0 | 549.4 | 1010 | 921.6 |
Frequently Asked Question
What is Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) total assets?
Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) total assets is 16647375283.000.
What is enterprise annual revenue?
The annual revenue is N/A.
What is firm profit margin?
Firm profit margin is 0.318.
What is company free cash flow?
The free cash flow is 3.367.
What is enterprise net profit margin?
The net profit margin is 0.031.
What is firm total revenue?
The total revenue is 0.045.
What is Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) net profit (net income)?
The net profit (net income) is 549441525.000.
What is firm total debt?
The total debt is 4886107552.000.
What is operating expences number?
The operating expences are 4717493463.000.
What is company cash figure?
Enretprise cash is 0.000.